AstraZeneca’s Imfinzi (durvalumab) has been granted priority review by the US Food and Drug Administration (FDA) to treat ...

AstraZeneca (LSE:AZN) recently reported robust earnings results, with significant year-over-year increases in sales, revenue, ...

AstraZeneca has proposed price cuts to its drugs in the United States, its CEO said on Tuesday, days after unveiling a $50 ...

Cambridge: AstraZeneca has announced that the company's supplemental Biologics License Application (sBLA) for Imfinzi ...

AstraZeneca posted $14.46 billion in Q2 revenue, reaffirming its 2025 outlook as the FDA advances Imfinzi in gastric cancer.

Pascal Soriot's comments came during AstraZeneca's Q2 earnings call in regard to President Donald Trump’s newly announced ...

AstraZeneca has received a positive recommendation from NICE for the use of Imfinzi (durvalumab) with Imjudo (tremelimumab) ...

The regulatory actions were based on results from the Phase III MATTERHORN trial (NCT04592913), which showed that a ...

AstraZeneca’s supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) has been accepted and granted Priority Review in the US for the treatment of patients with resectable, ...

AstraZeneca (($AZN)) has held its Q2 earnings call. Read on for the main highlights of the call. AstraZeneca’s recent earnings call showcased a ...

AstraZeneca CEO Pascal Soriot said it’s time for the U.S. to start paying more reasonable prices for new drugs, which are closer to what other wealthy countries pay, in a rare stance in an industry ...

The UK’s National Institute for Health and Care Excellence (NICE) has issued a positive recommendation for the use of ...